探索XIa因子抑制剂的治疗效用,以及XIa因子抑制剂的治疗效用
Jocelyn Edwards1, Jack Corey2, James C Coons3,4
1ChristianaCare, Newark, DE, USA.
概括
阿桑德西安是一种新型XIa因子抑制剂,在早期试验中显示出抗凝固药物的前景,并提高了安全性. 然而,与阿皮克萨班相比,一项针对心房的第三期试验因缺乏疗效而提前停止.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 血栓形成研究研究
背景情况:
- XIa因子抑制剂代表了一种针对病理性血栓的新型抗凝剂类.
- 传统的抗凝剂携带出血的风险,限制了它们的使用.
- 研究中的XIa因子抑制剂旨在提高抗血栓治疗的安全性.
研究的目的:
- 评估asundexian,一个口服的,每天服用一次的XIa因子抑制剂.
- 评估asundexian在各种临床环境中的疗效和安全性.
- 为了比较asundexian与标准抗凝药和安慰剂.
主要方法:
- 阿桑德西安被研究为口服,每天服用一次的药物.
- 第二阶段试验评估了XIa因子的抑制和安全性.
- 第三阶段试验 (OCEANIC-AF,OCEANIC-AFINA) 是为特定的适应症而设计的.
主要成果:
- 阿桑德西安在20-50毫克剂量时抑制了大约90%的XIa因子活性.
- 第二阶段试验表明,在心房动中,潜在的安全益处.
- 在其他指示中,阿桑德西安与抗血小板治疗没有显示出出血与安慰剂之间的差异.
结论:
- 由于阿桑德西安与阿皮克萨班在心房的中风预防方面无效,因此OCEANIC-AF 3 期试验被中止.
- 一项计划的第三期试验 (OCEANIC-AFINA) 将在高风险心房患者中比较阿桑德西安与安慰剂,这些患者不符合抗凝治疗的条件.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672
01:13Therapeutic Index
4.2K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166